Effect of Phospholipid Composition on Characterization of Liposomes Containing 9-Nitrocamptothecin

REFERENCES

• Balasubramanian S. V., Alderfer J. L., Straubinger R. M. Solvent- and concentration-dependent molecular interactions of Taxol (Paclitaxel). Journal of Pharmaceutical Science 1994; 83: 1470–1476
   PubMed Web of Science ®Google Scholar
• Burke T. G., Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. Journal of Medicinal Chemistry 1994; 37: 40–46
   PubMed Web of Science ®Google Scholar
• Cao Z., Harris N., Kozielski A., Vardeman D., Stelin J. S., Giovanella B. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity and antitumor activity. Journal of Medicinal Chemistry 1998; 41: 31–37
   PubMed Web of Science ®Google Scholar
• Chow D. S., Gong L., Wolfe M. D., Giovanella B. C. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitrocamptothecin. Annals NewYork Academy of Sciences 2000; 922: 164–174
   PubMed Web of Science ®Google Scholar
• Giovanella B. C., Stehlin J. S., Hinz H. R., Kozielski A. J., Harris N. J., Vardeman D. M. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(s)-camptothecin (Rubitecan). International Journal of Oncology 2002; 20: 81–88
   PubMed Web of Science ®Google Scholar
• Hertzberg R. P., Caranfa M. J., Holden K. G., Jakas D. R., Gallagher G., Mattern M. R., Mong S. M., Bartus J. O., Johnson R. K., Kingsbury W. D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. Journal of Medicinal Chemistry 1989; 32: 715–720
   PubMed Web of Science ®Google Scholar
• Hung C. L., Doniger J., Palini A., Snyder S. W., Radonovich M. F., Brady J. N., Pantazis P., Sadaie M. R. 9-Nitrocamptothecin inhibits HIV-1 replication in human peripheral blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy. Journal of Medical Virology 2001; 64: 238–244
   PubMed Web of Science ®Google Scholar
• Kan P., Wang A. J., Chen W. K., Tsa C. W. Liposome for incorporating large amounts of hydrophobic substances. US2004126886, 2004, July 1, 2004
   Google Scholar
• Konstadoulakis M. M., Antonakis P. T., Tsibloulis B. G., Stathopoulos G. P., Manouras A. P., Mylonaki D. B., Golematis B. X. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology 2001; 48: 417–420
   PubMed Web of Science ®Google Scholar
• Patel S. R., Beach J., Papadopoulos N., Burgess M. A., Trent J., Benjamin R. S. Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 2003; 97: 2848–2852
   PubMed Web of Science ®Google Scholar
• Punt C. J., Jonge M. J., Monfardini S., Daugaard G., Fiedler W., Baron B., Lacombe D., Fumoleau P. RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. European Journal of Cancer 2004; 40: 1332–1334
   PubMed Web of Science ®Google Scholar
• Raymond E., Campone M., Stupp R., Meten J., Chollet P., Lesimple T., Fety-Deporte R., Lacombe D., Paoletti X., Fumoleau P. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitrocamptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. European Journal of Cancer 2002; 38: 1348–1350
   PubMed Web of Science ®Google Scholar
• Schoffski P., Herr A., Vermorken J. B., Van den Brande J., Beijnen J. H., Rosing H., Volk J., Ganser A., Adank S., Botma H. J., Wanders J. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailiability of the oral camptothecin analogue. European Journal of Cancer 2002; 38: 807–813
   PubMed Web of Science ®Google Scholar
• Scott D. O., Bindra D. S., Stella V. J. Plasma pharmacokinetics of the lactone and carboxylate forms of 20(s)-camptothecin in anesthetized rats. Pharmaceutical Research 1993; 10: 1451–1457
   PubMed Web of Science ®Google Scholar
• Sha X., Fang X. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. International Journal of Pharmaceutics 2004; 272: 161–171
   PubMed Web of Science ®Google Scholar
• Ulukan H., Swaan P. W. Camptothecins: A review of their chemotherapeutic potential. Drugs 2002; 62: 2039–2057
   PubMed Web of Science ®Google Scholar
• Warner D. L., Burke T. G. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. Journal of Chromatography B 1997; 691: 161–171
   PubMed Web of Science ®Google Scholar
• Yang S. C., Zhu J. B., Lu Y., Liang B. W., Yang C. Z. Body distribution of camptothecin solid liquid nanoparticles after oral administration. Pharmaceutical Research 1999; 16: 751–757
   PubMed Web of Science ®Google Scholar
• Yang S. C., Zhu J. B. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Development and Industrial Pharmacy 2002; 28: 265–274
   PubMed Web of Science ®Google Scholar
• Zhang J. A., Xuan T., Parmar M., Ma L., Ugwu S., Ali S., Ahmad I. Development and characterization of a novel liposome-based formulation of SN-38. International Journal of Pharmaceutics 2004; 270: 93–107
   PubMed Web of Science ®Google Scholar
• Zhong D. F., Li K., Xu J. H., Du Y., Zhang Y. F. Pharmacokinetics of 9-nitro-20(s)-camptothecin in rats. Acta Pharmacologica Sinica 2003; 24: 256–262
   PubMed Web of Science ®Google Scholar